Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-02
2011-08-02
Haddad, Maher (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S013500, C424S192100
Reexamination Certificate
active
07988973
ABSTRACT:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
REFERENCES:
patent: 4973577 (1990-11-01), Vale, Jr. et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5658876 (1997-08-01), Crowley et al.
patent: 5824637 (1998-10-01), Crowley et al.
patent: 5847078 (1998-12-01), Eto et al.
patent: 5885794 (1999-03-01), Mathews et al.
patent: 6093547 (2000-07-01), Jin et al.
patent: 6132988 (2000-10-01), Sugino et al.
patent: 6162896 (2000-12-01), Mathews et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6599876 (2003-07-01), Kojima et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6692925 (2004-02-01), Miyazono et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7192717 (2007-03-01), Hill et al.
patent: 7202210 (2007-04-01), Wolfman et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7320789 (2008-01-01), Aghajanian et al.
patent: 7560441 (2009-07-01), Wolfman et al.
patent: 7612041 (2009-11-01), Knopf et al.
patent: 2003/0083251 (2003-05-01), Westenfelder
patent: 2003/0144203 (2003-07-01), Bowen
patent: 2004/0197828 (2004-10-01), Gaddy
patent: 2004/0209805 (2004-10-01), Phillips et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0068468 (2006-03-01), Knopf et al.
patent: 2006/0210657 (2006-09-01), Chou
patent: 2007/0048830 (2007-03-01), Gilbert et al.
patent: 2007/0149455 (2007-06-01), Wolfman et al.
patent: 2007/0172956 (2007-07-01), Magari et al.
patent: 2007/0184052 (2007-08-01), Lin et al.
patent: 2007/0249022 (2007-10-01), Knopf et al.
patent: 2007/0275895 (2007-11-01), Duan et al.
patent: 2007/0292885 (2007-12-01), Bejanin et al.
patent: 2008/0021104 (2008-01-01), Tarallo
patent: 2008/0075692 (2008-03-01), Perrine
patent: 2008/0089897 (2008-04-01), Wolfman
patent: 2008/0139590 (2008-06-01), Qian et al.
patent: 2009/0005308 (2009-01-01), Knopf et al.
patent: 2009/0017019 (2009-01-01), Shields et al.
patent: 2009/0047281 (2009-02-01), Sherman
patent: 2009/0074768 (2009-03-01), Knopf et al.
patent: 2009/0087433 (2009-04-01), Wolfman et al.
patent: 2009/0098113 (2009-04-01), Knopf et al.
patent: 2009/0099086 (2009-04-01), Knopf et al.
patent: 2009/0118188 (2009-05-01), Knopf et al.
patent: 2009/0142333 (2009-06-01), Knopf et al.
patent: 2009/0148436 (2009-06-01), LaVallie et al.
patent: 2009/0163417 (2009-06-01), Sherman
patent: 1174149 (2002-01-01), None
patent: WO-9220793 (1992-11-01), None
patent: WO-9510611 (1995-04-01), None
patent: WO-95/29685 (1995-11-01), None
patent: WO-9906559 (1999-02-01), None
patent: WO-0043781 (2000-07-01), None
patent: WO-0210214 (2002-02-01), None
patent: WO-0243759 (2002-06-01), None
patent: WO-02085306 (2002-10-01), None
patent: WO-03006057 (2003-01-01), None
patent: WO-03/053219 (2003-07-01), None
patent: WO-03072808 (2003-09-01), None
patent: WO-2004/039948 (2004-05-01), None
patent: WO-2004108157 (2004-12-01), None
patent: WO-2005/009460 (2005-02-01), None
patent: WO-2005/028517 (2005-03-01), None
patent: WO-2005094871 (2005-10-01), None
patent: WO-2005097825 (2005-10-01), None
patent: WO-2006002387 (2006-01-01), None
patent: WO-2006/012627 (2006-02-01), None
patent: WO-2006039400 (2006-04-01), None
patent: WO-2006083183 (2006-08-01), None
patent: WO-2006088972 (2006-08-01), None
patent: WO-2007/062188 (2007-05-01), None
patent: WO-2007053775 (2007-05-01), None
patent: WO-2007067616 (2007-06-01), None
patent: WO-2008100384 (2008-02-01), None
patent: WO-2008031061 (2008-03-01), None
patent: WO-2008060139 (2008-05-01), None
patent: WO-2008076437 (2008-06-01), None
patent: WO-2008097541 (2008-08-01), None
patent: WO-2008109167 (2008-09-01), None
patent: WO-2009019504 (2009-02-01), None
patent: WO-2009019505 (2009-02-01), None
patent: WO-2009137613 (2009-11-01), None
Kuntz. Structure-based strategies for drug design and discovery. Science. 1992 257(5073):1078-1082.
Miller et al Ligand binding to proteins: the binding landscape model. Protein Sci. Oct. 1997;6(10):2166-79.
Wang et al. A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. JBC 276:49213-49220, 2001.
Kim et al. Type IIa IgG-Fc Fusion Protein, Increases Hemoglobin and Hematocrit Levels in Postmenopausal Healthy Women. Blood, (Nov. 16, 2008) vol. 112, No. 11, pp. 1316, 50th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA, USA.
Berenson Jr. Multiple Myeloma: Plasma Cell Disorders: Merck Manual Professional. pp. 1-5. Jul. 2008.
Coerver, et al., “Activin Signaling through Activin Receptor Type II Causes the Cachexia-Like Symptoms in Inhibin-Deficient Mice,” 10(5):534-543 (1996).
Harrison, et al., “Antagonists of activin signaling: mechanisms and potential biological applications,” TRENDS in Endocrinology and Metabolism, 16(2):73-78 (2005).
Li, et al., “Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein,” Molecular Human Reproduction, 13(9):675-683 (2007).
Welt, et al., “Activin: an endocrine or panacrine agent?,” European Journal of Endocrinology 139:469-471 (1998).
Ludlow, H., et al., “Development of a new antibody to the human inhibin/activin βB subunit and its application to improved inhibin B ELISAs,” J. Immunol. Methods, 329:102-111 (2008).
Shiozaki, M., et al., “In Vivo Treatment With Erythroid Differentiation Factor (EDF / Activin A) Increases Erythroid Precursors (CFU-E and BFU-E) in Mice,” Biochemical and Biophysical Research Communications, 165(3):1155-1161 (1989).
Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation, Acceleron Pharma, pp. 1-2, retrieved from the Internet, www.acceleronpharma.com/contents
ews/press-releases/detail.jsp/q
ews-id/47> (2007).
Centrella et al., “Activin-A Binding and Biochemical Effects in Osteoblast-Enriched Cultures from Fetal-Rat Parietal Bone,” Molecular and Cellular Biology, 11(1):250-58 (1991).
Chen, Y.G., et al. “Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin,” Exp. Biol. Med., 227(2):75-87 (2002).
Daluiski et al., “Bone Morphogenetic Protein-3 is a Negative Regulator of Bone Density,” Nature Genetics, 27:84-88 (2001).
del Re et al., “Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System,” The Journal of Biological Chemistry, 279(51):53126-53135 (2004).
Donaldson, et al., “Activin and inhibin binding to the soluble extracellular domain of activin receptor II”, Endocrinology 140(4):1760-1766(1999).
Donaldson, et al., “Molecular Cloning and Binding Properties of the Human Type II Activin Receptor”, Biochemical and Biophysical Research Communications, 184(1):310-316(1992).
Fafioffe, et al.,“Activin and inhibin receptor gene expression in the ewe pituitary throughout the oestrous cycle,” Journal of Endocrinology, vol. 182, pp. 55-68 (2004).
Fuller et al., “Activin A Is an Essential Cofactor for Osteoclast Induction,” Biochemical and Biophysical Research Communications, 268:2-7 (2000).
Funaba et al., “Expression and Localization of Activin Receptors During Endochondral Bone Development,” European Journal of Endocrinology, 144:63-71 (2001).
Gaddy-Kurten et al., “Inhibin Suppresses and Activin Stimulates Osteoblastogenesis and Osteoclastogenesis in Murine Bone Marrow Cultures,” Endocrinology, 143(1):74-83 (2002).
Gamer et al., “BMP-3 is a Novel Inhibitor of Both Activin and BMP-4 Signaling in Xenopus Embryos,” Developmental Biology, 285:156-168 (2005).
Ge, G., et al., “GDF11 Forms a Bone Morphogenetic Protein
Acceleron Pharma Inc.
Haddad Maher
Ropes & Gray LLP
LandOfFree
Activin-ActRII antagonists and uses for increasing red blood... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activin-ActRII antagonists and uses for increasing red blood..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activin-ActRII antagonists and uses for increasing red blood... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2713029